Jasper Therapeutics, Inc. (AMHCU) [Rocket]

Overview

Jasper Therapeutics, Inc. (AMHCU)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/13/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/13/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/13/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/13/2023	144	Form 144 - Report of proposed sale of securities:
10/10/2023	SC 13G	SPHERA FUNDS MANAGEMENT LTD. reports a 5.1% stake in Jasper Therapeutics, Inc.
10/10/2023	8-K	Investor presentation
10/10/2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20
Revenues	2.2	39.2	-11.1
Revenue growth	-94.4%	-452.8%
Cost of goods sold	-53.0	0.0	-85.4
Gross profit	55.2	39.2	74.3
Gross margin	2507.6%	100.0%	-669.6%
Selling, general and administrative	18.3	13.0	6.0
Research and development	35.5	25.6	16.1
General and administrative	16.6	11.4	5.5
EBIT	-49.8	-36.2	-20.7
EBIT margin	-2262.4%	-92.5%	186.4%
Pre-tax income	-37.7	-30.6	-31.7
Income taxes	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%
Net income	-37.7	-30.6	-31.7
Net margin	-1713.0%	-78.2%	285.4%

Diluted EPS	($1.03)	($2.69)	($5.17)
Shares outstanding (diluted)	36.5	11.4	6.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.